Señales en vivo de ARDX | Maximiza tus Ganancias con Getagraph.com

VENDER 949 min ago

@ $9.16

Emitido: 7 may 2024 @ 14:59

Retorno: 1.64%

Señal anterior: may 7 - 13:25

Señal anterior: Comprar

Retorno: 0.38 %

Live Chart Being Loaded With Signals

Commentary (7 may 2024 @ 16:00):

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally...

Stats
Volumen de hoy	4.85M
Volumen promedio	6.09M
Capitalización de mercado	2.18B
EPS	$0 ( 2024-05-02 )
Próxima fecha de ganancias	( $0 ) 2024-07-31
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-33.25
ATR14	$0.248 (2.67%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-03	Grammer Elizabeth A	Sell	45 000	Common Stock
2024-05-03	Williams Laura A	Buy	30 000	Common Stock
2024-05-03	Williams Laura A	Sell	39 949	Common Stock
2024-05-03	Williams Laura A	Sell	30 000	Stock Option (Right to Buy)
2024-04-29	Raab Michael	Buy	30 000	Common Stock

INSIDER POWER
60.60
Last 99 transactions
Buy: 4 060 095 \| Sell: 992 569

Volumen Correlación

Largo: 0.93 (very strong)

Corto: -0.41 (neutral)

Signal:(64) Neutral

Ardelyx Inc Correlación

10 Correlaciones Más Positivas
MLAI	0.964
KAII	0.959
FRSG	0.959
TCMD	0.956
ACQR	0.954
NVSA	0.952
ARRW	0.952
GLLI	0.952
TBSA	0.951
CPAQ	0.95

10 Correlaciones Más Negativas
CSSEP	-0.96
EQBK	-0.957
FCBC	-0.951
MBOT	-0.949
DRUG	-0.945
BMRA	-0.944
EVLO	-0.942
SPFI	-0.941
BWB	-0.94
HRMY	-0.939

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Ardelyx Inc Correlación - Moneda/Commodity

0.56
( weak )

-0.06
( neutral )

0.00
( neutral )

-0.03
( neutral )

0.72
( moderate )

0.86
( strong )

Ardelyx Inc Finanzas

Annual	2023
Ingresos:	$124.46M
Beneficio Bruto:	$106.66M (85.70 %)
EPS:	$-0.300

FY	2023
Ingresos:	$124.46M
Beneficio Bruto:	$106.66M (85.70 %)
EPS:	$-0.300

FY	2022
Ingresos:	$52.16M
Beneficio Bruto:	$48.04M (92.11 %)
EPS:	$-0.420

FY	2021
Ingresos:	$10.10M
Beneficio Bruto:	$9.10M (90.10 %)
EPS:	$-1.520

Financial Reports:

No articles found.

Ardelyx Inc

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.